Teva Pharmaceutical Industries : FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-ERIC HUGHES

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549
	INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the
	Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden hours
per response...	0.5

1. Name and Address of Reporting Person	2. Date of Event Requiring
Hughes	Eric	A.	Statement (Month/Day/Year)
			08/01/2022

3. Issuer Name and Ticker or Trading Symbol

Teva Pharmaceutical Industries Ltd. [TEVA]

(Last)	(First)	(Middle)
Teva Pharmaceutical Industries Ltd. , C/O
124 Dvora HaNevi'a St.
(Street)
Tel Aviv	L3
(City)	(State)	(Zip)

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director

____ 10% Owner

• Officer (give title____below) Other (specify below)

See "Remarks"

1. If Amendment, Date Original Filed(Month/Day/Year)
2. Individual or Joint/Group Filing (Check

Applicable Line)

• Form filed by One Reporting Person
  ____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

	1.Title of Security	2. Amount of Securities Beneficially	3. Ownership	4. Nature of Indirect Beneficial Ownership
	(Instr. 4)	Owned	Form: Direct (D)	(Instr. 5)
		(Instr. 4)	or Indirect (I)
			(Instr. 5)

Page 1 of 4.

Table II - Derivative Securities Beneficially Owned ( e.g., puts, calls, warrants, options, convertible securities)

	1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of Securities	4. Conversion or	5. Ownership	6. Nature of Indirect Beneficial
	(Instr. 4)	Expiration Date	Underlying Derivative Security	Exercise Price of	Form of	Ownership
		(Month/Day/Year)	(Instr. 4)	Derivative	Derivative	(Instr. 5)
						Security	Security: Direct
		Date	Expiration		Amount or Number of
		Title		(D) or Indirect (I)
		Exercisable	Date	Shares		(Instr. 5)

Explanation of Responses:

Remarks:

Executive Vice President, Global R&D and Chief Medical Officer

/s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes	08/03/2022
**Signature of Reporting Person	Date

• If the form is filed by more than one reporting person, see Instruction 5(b)(v).

• Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.
  Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Page 2 of 4.

POWER OF ATTORNEY

FOR SECTION 16 REPORTING OBLIGATIONS

KNOW ALL BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Dov Bergwerk, Shira Aran-Porat and Dikla Tadmor signing singly, as the undersigneds true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

1. prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Teva Pharmaceutical Industries Limited, a company incorporated under the law of Israel, or any successor thereto (the "Company"), with the U.S. Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act");
2. seek or obtain, as the undersigneds representative and on the undersigneds behalf, information of transactions in the Companys securities from any third-party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
3. perform any and all other acts which in the discretion of such attorney-in-fact is necessary or desirable for and on behalf of the undersigned in connection with the foregoing.
   The undersigned acknowledges that:

1. this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in his or her discretion on information provided to such attorney-in-fact without independent verification of such information;
2. any documents prepared, executed, acknowledged and/or delivered by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;
3. neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigneds responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and
4. this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigneds obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.
   The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Power of Attorney.
   This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day of July, 2022.

By: /s/ Eric A. Hughes

Name: Eric A. Hughes

Title: Executive Vice President, Global R&D and Chief Medical Officer

Page 3 of 4.

Page 4 of 4.